[go: up one dir, main page]

BR0017030A - Derivados de tiazolilamida - Google Patents

Derivados de tiazolilamida

Info

Publication number
BR0017030A
BR0017030A BR0017030-5A BR0017030A BR0017030A BR 0017030 A BR0017030 A BR 0017030A BR 0017030 A BR0017030 A BR 0017030A BR 0017030 A BR0017030 A BR 0017030A
Authority
BR
Brazil
Prior art keywords
thiazolylamide
derivatives
thiazolylamide derivatives
medicaments
novel
Prior art date
Application number
BR0017030-5A
Other languages
English (en)
Other versions
BR0017030B1 (pt
BR0017030B8 (pt
Inventor
Ruediger Fischer
Gerald Kleymann
Ulrich Betz
Judith Baumeister
Wolfgang Bender
Peter Eckenberg
Gabriele Handke
Martin Hendrix
Kerstin Henninger
Axel Jensen
Joerg Keldenich
Udo Schneider
Olaf Weber
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19962532A external-priority patent/DE19962532A1/de
Priority claimed from DE10039265A external-priority patent/DE10039265A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR0017030A publication Critical patent/BR0017030A/pt
Publication of BR0017030B1 publication Critical patent/BR0017030B1/pt
Publication of BR0017030B8 publication Critical patent/BR0017030B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54Nitrogen and either oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE TIAZOLILAMIDA". A presente invenção refere-se a novos derivados de tiazolilamida, um processo para a sua preparação bem como seu emprego como medicamentos, especialmente como medicamentos antivirais.
BRPI0017030A 1999-12-23 2000-12-12 derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos BR0017030B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19962532A DE19962532A1 (de) 1999-12-23 1999-12-23 Thiazolylamid-Derivate
DE10039265A DE10039265A1 (de) 2000-08-11 2000-08-11 Thiazolylamid-Derivate
PCT/EP2000/012564 WO2001047904A1 (de) 1999-12-23 2000-12-12 Thiazolylamid-derivate

Publications (3)

Publication Number Publication Date
BR0017030A true BR0017030A (pt) 2003-01-07
BR0017030B1 BR0017030B1 (pt) 2013-10-01
BR0017030B8 BR0017030B8 (pt) 2021-05-25

Family

ID=26006669

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0017030A BR0017030B8 (pt) 1999-12-23 2000-12-12 derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos

Country Status (26)

Country Link
US (1) US7105553B2 (pt)
EP (1) EP1244641B1 (pt)
JP (1) JP4726175B2 (pt)
KR (1) KR100768361B1 (pt)
CN (1) CN1235890C (pt)
AR (1) AR029210A1 (pt)
AT (1) ATE293104T1 (pt)
AU (1) AU784286B2 (pt)
BR (1) BR0017030B8 (pt)
CA (1) CA2396720C (pt)
CO (1) CO5261491A1 (pt)
DE (1) DE50010060D1 (pt)
DK (1) DK1244641T3 (pt)
DO (1) DOP2000000109A (pt)
ES (1) ES2240233T3 (pt)
IL (2) IL149897A0 (pt)
MX (1) MXPA02006243A (pt)
MY (1) MY134880A (pt)
NZ (1) NZ519701A (pt)
PE (1) PE20010964A1 (pt)
PL (1) PL208707B1 (pt)
PT (1) PT1244641E (pt)
SV (1) SV2002000249A (pt)
TW (1) TWI256951B (pt)
UY (1) UY26495A1 (pt)
WO (1) WO2001047904A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000259734A1 (en) * 2000-06-15 2001-12-24 Gerald Kleymann Method for identifying compounds with anti-herpes activity
DE10129714A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10131128A1 (de) * 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
DK2578229T3 (da) * 2004-09-09 2013-10-07 Novartis Vaccines & Diagnostic Faldende potentielle iatrogene risici associeret med vaccine-antigener
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
WO2007037898A2 (en) * 2005-08-29 2007-04-05 Housey Pharmaceuticals Inc Theramutein modulators
BRPI0611187A2 (pt) * 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
US20070032488A1 (en) * 2005-08-05 2007-02-08 Genelabs Technologies, Inc. 6-Membered aryl and heteroaryl derivatives for treating viruses
PL2489350T3 (pl) * 2006-03-17 2014-08-29 Cardioxyl Pharmaceuticals Inc Pochodne N-hydroksylosulfonamidu jako nowe, fizjologicznie użyteczne donory nitroksylu
US20100051879A1 (en) * 2006-11-22 2010-03-04 The Regents od the Univesity of California Functionalized Boron Nitride Nanotubes
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
MX2015010339A (es) * 2013-02-12 2015-11-16 Aicuris Gmbh & Co Kg Inhibidores de helicasa-primasa para su uso en un metodo para tratar la enfermedad de alzheimer.
BR112017000285A2 (pt) * 2014-07-07 2017-10-31 Prophylaxis LLC métodos de tratamento da profilaxia viral e kits de profilaxia de pré-exposição
EA035401B1 (ru) * 2016-04-06 2020-06-08 Инновейтив Молекьюлз Гмбх Производные аминотиазола, полученные в качестве противовирусных средств
WO2018095576A1 (en) 2016-11-28 2018-05-31 Aicuris Anti-Infective Cures Gmbh Topical pharmaceutical formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide
RS61905B1 (sr) * 2016-11-28 2021-06-30 Aicuris Gmbh & Co Kg Hemihidrat slobodne baze n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida, postupci njegove proizvodnje i upotrebe
CN117186085A (zh) * 2016-11-28 2023-12-08 艾库里斯有限及两合公司 普瑞利韦硫酸盐、其药物制剂、制造方法及治疗疱疹病毒的用途
CN110225781B (zh) * 2017-01-09 2022-05-17 辉诺生物医药科技(杭州)有限公司 噻唑衍生物及其应用
MD3692039T2 (ro) 2017-10-05 2023-05-31 Innovative Molecules Gmbh Enantiomerii tiazolilor substituiți ca compuși antivirali
AU2019297214B2 (en) 2018-07-06 2022-07-07 Phaeno Therapeutics Co., Ltd. Crystal forms of thiazole compound and application thereof
KR20220160024A (ko) 2020-03-26 2022-12-05 아이쿠리스 게엠베하 운트 코. 카게 N-[5-(아미노술포닐)-4-메틸-1,3-티아졸-2-일]-n-메틸-2-[4-(2-피리디닐)페닐]아세트아미드 반수화물을 포함하는 안과용 제제
EP3925595A1 (en) 2020-06-17 2021-12-22 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate
WO2022090409A1 (en) 2020-10-29 2022-05-05 Innovative Molecules Gmbh Deuterated aminothiazole compounds as antiviral compounds
KR20240134979A (ko) 2022-01-17 2024-09-10 이노베이티브 몰리큘스 게엠베하 헬리카제-프라이마제 억제제의 고체 결정형 및 이의 제조 방법
CN119546574A (zh) 2022-05-20 2025-02-28 吉利德科学公司 抗病毒吲哚啉基化合物和其用途
PE20251667A1 (es) 2022-08-29 2025-06-30 Assembly Biosciences Inc Compuestos ciclicos de urea tiazolilo para el tratamiento del hsv
JP2025530762A (ja) 2022-08-29 2025-09-17 アセンブリー・バイオサイエンシーズ・インコーポレイテッド ヘルペスウイルス用医薬組成物
EP4581030A1 (en) 2022-08-29 2025-07-09 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
WO2024047507A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
WO2024224304A1 (en) 2023-04-26 2024-10-31 Assembly Biosciences, Inc. Oral pharmaceutical compositions
WO2025046457A1 (en) 2023-08-28 2025-03-06 Assembly Biosciences, Inc. A crystalline form of 2-(3-(2,,5'-difluoro-[1,1'-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2h)-yl)-4-methylthiazole-5-sulfonamide
WO2025046456A1 (en) 2023-08-28 2025-03-06 Assembly Biosciences, Inc. A crystalline form of 2-(3-(2,,5'-difluoro-[1,1'-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2h)-yl)-4-methylthiazole-5-sulfonamide
WO2025111598A1 (en) 2023-11-22 2025-05-30 Assembly Biosciences, Inc. Azetidine compounds for treatment of hsv
WO2025172927A1 (en) 2024-02-16 2025-08-21 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus
WO2026015761A1 (en) 2024-07-12 2026-01-15 Assembly Biosciences, Inc. Cyclic urea thiazolyl compound for treatment of viral infections unresponsive to treatment with a first antiviral therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2075560A5 (pt) 1970-01-16 1971-10-08 Shell Int Research
US3658830A (en) 1970-01-16 1972-04-25 Shell Oil Co 5-(substituted mercapto sulfiny sulfonyl or sulfamoyl)
US3717651A (en) 1970-04-20 1973-02-20 Shell Oil Co Thiazoles
US3847588A (en) 1970-04-20 1974-11-12 Shell Oil Co Thiazoles herbicidal
DE69624728T2 (de) 1995-12-29 2003-07-10 Boehringer Ingelheim (Canada) Ltd., Laval Phenyl thiazol derivate mit antiherpesvirus eigenschaften
US5705344A (en) 1996-03-14 1998-01-06 Tularik, Inc. High-throughput screening assay for inhibitors of nucleic acid helicases
GB2311069A (en) 1996-03-14 1997-09-17 Merck & Co Inc Primase isolated from human cytomegalovirus (HCMV)
GB2311068A (en) 1996-03-14 1997-09-17 Merck & Co Inc Helicase isolated from human cytomegalovirus (HCMV)
CA2223032A1 (en) 1997-02-21 1998-08-21 Smithkline Beecham Corporation Use of hsv-1 ul-15 and vp5 in identifying anti-viral agents
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
WO1999042455A1 (en) 1998-02-19 1999-08-26 Tularik Inc. Antiviral agents
DK1064273T3 (da) 1998-03-19 2003-03-31 Upjohn Co 1,3,4-Thiadiazoler, som er nyttige til behandling af CMV-infektioner
WO2000053591A1 (de) 1999-03-08 2000-09-14 Bayer Aktiengesellschaft Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel

Also Published As

Publication number Publication date
IL149897A (en) 2008-08-07
JP2003519134A (ja) 2003-06-17
AU3157401A (en) 2001-07-09
JP4726175B2 (ja) 2011-07-20
BR0017030B1 (pt) 2013-10-01
KR100768361B1 (ko) 2007-10-18
CN1235890C (zh) 2006-01-11
SV2002000249A (es) 2002-06-07
DE50010060D1 (de) 2005-05-19
NZ519701A (en) 2004-05-28
PE20010964A1 (es) 2001-11-10
MY134880A (en) 2007-12-31
PL208707B1 (pl) 2011-05-31
HK1057552A1 (en) 2004-04-08
PL356484A1 (en) 2004-06-28
DK1244641T3 (da) 2005-07-11
PT1244641E (pt) 2005-08-31
MXPA02006243A (es) 2003-01-28
TWI256951B (en) 2006-06-21
ES2240233T3 (es) 2005-10-16
DOP2000000109A (es) 2002-08-30
KR20020067568A (ko) 2002-08-22
CA2396720C (en) 2009-09-22
US20040006076A1 (en) 2004-01-08
CA2396720A1 (en) 2001-07-05
CO5261491A1 (es) 2003-03-31
IL149897A0 (en) 2002-11-10
WO2001047904A1 (de) 2001-07-05
EP1244641A1 (de) 2002-10-02
ATE293104T1 (de) 2005-04-15
UY26495A1 (es) 2001-07-31
AR029210A1 (es) 2003-06-18
BR0017030B8 (pt) 2021-05-25
CN1434812A (zh) 2003-08-06
US7105553B2 (en) 2006-09-12
AU784286B2 (en) 2006-03-02
EP1244641B1 (de) 2005-04-13

Similar Documents

Publication Publication Date Title
BR0017030A (pt) Derivados de tiazolilamida
BR0214870A (pt) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituìdas e aplicação das mesmas
MX9304819A (es) Nuevos derivados de xantina y procedimiento para su preparacion.
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
ECSP034460A (es) Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como antibacterianos
BR0111319A (pt) Composto, processo para preparar um composto, uso de um composto, processo para preparar um sal de um composto, e, composto intermediário
BR9911914B1 (pt) n-arilamidas do ácido sulfonilaminocarboxìlico substituìdas por enxofre, processo para sua preparação, bem como preparações farmacêuticas que compreendem as mesmas.
BRPI0407967A (pt) processo de uma etapa para a preparação de derivados anticonvulsivantes
BR0013311A (pt) Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor
PT1259498E (pt) Derivados do 8,8a-di-hidroindeno[1,2-d]tiazole substituidos na posicao 8a, processo para a sua preparacao e sua utilizacao como medicamentos, p. ex. como anorecticos
BR0008682A (pt) 3-amino-3-arilpropan-1-ol, processo para sua produção, seu uso e medicamento
BR0108990A (pt) Processo para preparação de derivados de pirimidona com atividade antifungos
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
BR0208534A (pt) Processo para preparação de 4,6-diaminopirimido[5,4-d]pirimidinas
BR0013175A (pt) Derivados de vitamina d com sub-estruturas cìclicas na cadeias laterais, processos e produtos intermediários para a sua preparação e a utilização para a preparação de medicamentos
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
PT1210384E (pt) Composicoes de revestimento inorganicas, um processo para a sua preparacao bem como a sua utilizacao
BR0013313A (pt) Derivados substituìdos de pirrolidino-2,3,4- triona-3-oxina eficazes como antagonistas de receptores de nmda
BR0016942A (pt) Derivados substituìdos de aminometil-fenil-ciclohexano
BR0113259A (pt) Processo para a preparação de um composto, composto e processo para a preparação de compostos
BR0012622A (pt) Derivados de 3-amino-2-benzil-1-fenil-propano
BR9705509B1 (pt) derivados de 4-hidràxi-piperidina, processo para a preparaÇço dos mesmos, bem como medicamento contendo os mesmos.
BR0013084A (pt) Heterociclil-2h-cromenos substituìdos
BR9810407A (pt) Compostos fluormetoximino

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: AICURIS GMBH AND CO. KG (DE)

Free format text: TRANSFERIDO DE: BAYER AKTIENGESELLSCHAFT

B25G Requested change of headquarter approved

Owner name: AICURIS GMBH AND CO. KG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070107873/RJ DE 03/08/2007.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/10/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/12/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 12/12/2020